Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Briacell Therapeutics Corp
NASDAQ BCTX
Data sourced from
and
and
Briacell Therapeutics Corp Revenue Per Share for the year ending July 31, 2023: USD 0.00
Briacell Therapeutics Corp Revenue Per Share is USD 0.00 for the year ending July 31, 2023, a 0.00% change year over year. Revenue per share measures the amount of revenue generated by a company per outstanding share. It is calculated by dividing the revenue by the number of outstanding shares (weighted average). This ratio provides insights into the company's revenue generation on a per-share basis. A higher revenue per share indicates stronger revenue performance and potentially higher value per share for investors.
-
Briacell Therapeutics Corp Revenue Per Share for the year ending July 31, 2022 was USD 0.00, a 0.00% change year over year.
-
Briacell Therapeutics Corp Revenue Per Share for the year ending July 31, 2021 was USD 0.00, a 0.00% change year over year.
-
Briacell Therapeutics Corp Revenue Per Share for the year ending July 31, 2020 was USD 0.00, a 0.00% change year over year.
-
Briacell Therapeutics Corp Revenue Per Share for the year ending July 31, 2019 was USD 0.00, a 0.00% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: BCTX
| CEO | Dr. William V. Williams M.D. |
| IPO Date | Feb. 24, 2021 |
| Location | Canada |
| Headquarters | Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1 |
| Employees | 16 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Key trends
Similar companies
Day One Biopharmaceuticals Inc
NA
NA
Hepion Pharmaceuticals Inc
NA
NA
StockViz Staff
September 16, 2024
Any question? Send us an email